Tests tirzepatide for weight loss and fat tissue health in adults with obesity
Compares tirzepatide with a low-calorie diet in adults with overweight or obesity.
Key facts
- Who runs it
- Stanford University
- Where
- Palo Alto, United StatesSee the site
- Trial code
- Registry title
- Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 66 people, planned
- Started
- 9 Nov 2023
- Expected to end
- Dec 2029
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Tirzepatide
- Record updated
- 4 December 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with overweight or obesity who do not have diabetes. It tests tirzepatide against a low-calorie diet for 22 weeks.
- Age
- 18 to 70 years
- Sex
- All sexes
- Disease stage
- BMI 27-39.9 kg/m2. With BMI 30-39.9 kg/m2 no extra risk factor is needed. With BMI 27-29.9 kg/m2 at least one weight-related risk factor is needed, such as high blood pressure, abnormal blood fats, prediabetes, sleep apnea, fatty liver, gallstones or osteoarthritis.
- Earlier treatment
- No bariatric surgery or liposuction. No weight loss or diabetes-causing medicines, including GLP1 analogs, now or in the past three months. No glucose lowering medicines.
- Biomarker or test result
- Fasting plasma glucose below 126 mg/dL (7 mmol/L) (not diabetic).
Main reasons for not taking part
- Prior bariatric surgery or liposuction
- Body weight change of more than 2 kg (4 lb) in the past 6 weeks
- Unstable high blood pressure (above 160/100 mm Hg)
- Pregnancy or breastfeeding
- Heavy alcohol use, active eating or psychiatric disorder, or major organ disease
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- nondiabetic as defined by fasting plasma glucose < 126 mg/dL while off all glucose lowering medications
- BMI 27-39.9 kg/m2. Individuals with obesity (BMI 30-39.9 kg/m2) are not required to have an additional risk factor but those who are overweight (27-29.9 kg/m2) must have at least one weight-related factor as follows: hypertension defined as physician-diagnosed and taking antihypertensive medication or SBP> 130 or DBP > 80 mm Hg; dyslipidemia defined as physician diagnosed and taking medication or LDL > 160 mg/dL, TG > 150 mg/dL, HDL < 50 or < 40 mg/dL for women and men, respectively; prediabetes defined as fasting glucose 100-125 mg/dL off all antidiabetic or diabetogenic medications, physician diagnosed obstructive sleep apnea, non-alcoholic fatty liver disease, history of gallstones, and osteoarthritis
- Age 18-70
- Pre and postmenopausal women will be eligible and details of last menstrual period and/or hormone replacement collected for statistical adjustment and formal testing for effect modification
Who cannot take part
- prior bariatric surgery or liposuction
- use (current or within the past three months) of diabetogenic or weight loss medications, including GLP1 analogs
- unstable hypertension (defined as BP >160/100 mm Hg)
- major organ disease
- chronic inflammatory conditions
- active malignancy undergoing treatment
- active eating or psychiatric disorder
- unstable body weight defined as self-reported weight change >2 kg over the past 6 weeks
- pregnancy/lactation
- heavy alcohol use (>2 drinks/day for women and > 3 drinks/day for men) will be excluded
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Where in United States
- Clinical and Translational Research UnitPalo Alto, United StatesContact: Nicole Turk, BSTaking people
About the trial
What the trial wants to find out
Obesity, affecting 40% of US adults and costing 173b annually, represents a significant health care burden (1). It is associated with increased risk for multiple chronic diseases including hypertension, type 2 diabetes (T2D), cardiovascular disease, and NAFLD, as well as cancer, osteoarthritis, and obstructive sleep apnea. The investigators plan to test the hypothesis that tirzepatide, a dual GLP/GIP agonist, improves metabolic health (insulin resistance and regional fat distribution and cardiovascular risk profile) not only by inducing weight loss via GLP1-agonism, but also via beneficial cellular and molecular changes in adipose tissue, given that GIP binds receptors in human fat cells. Based on studies in mice showing that GIP alone or tirzepitide treatment decreases inflammation, increases lipid buffering (fat storage in the fat cells instead of releasing it into the bloodstream), and improves glucose homeostasis. The investigators believe that the GIP component of tirzepatide will make fat cells healthier and reverse lipotoxicity, which is one of the mechanisms by which obesity leads to insulin resistance, disordered regional fat distribution, and type 2 diabetes. To date, the effect of dual GLP1 and GIP agonist treatment on adipose tissue has not been evaluated in humans. Given the existing but limited data, dual GIP/GLP-1 agonist treatment in obese humans with metabolic risk factors is an attractive pharmacologic candidate that would lead to both weight loss and healthier fat, potentially offering uniquely powerful synergistic clinical benefits. It is thus of tremendous importance to define the biological effects of dual-agonist treatment on human adipose tissue structure and function, as well as related improvements in regional fat distribution and systemic adipose and muscle insulin sensitivity. In this study, the investigators will randomize overweight (with risk factors) or obese nondiabetic individuals to hypocaloric diet or tirzepatide for 22 weeks with matched weight loss for the first 6 weeks. The investigators will quantify insulin resistance, fat and lean mass, including regional fat distribution, and changes in adipose tissue (needle biopsy from abdominal fat tissue) to see if tirzepatide effects differ from dietary weight loss.
The 2 groups in the trial
- 2.5 mg (up to 15 mg) TirzepatideTreatment being tested
Patients assigned to tirzepatide will undergo dose titration starting with 2.5 mg per day with an increase every four weeks if tolerated by nausea. During the first 6 weeks, weight loss must be matched with the dietary weight loss arm at 0.6 kg/week. Participants will be seen every two weeks to review diet and physical activity, evaluate tolerability/side effects, and obtain morning weight. If weight loss is greater than 0.6 kg/week, recommendations to increase caloric intake will be made through the week 6 visits that repeat baseline testings (biopsy, metabolic tests, and regional fat scans). After the 6th week, weight loss can occur naturally without any restrictions (no further matching to the dietary weight loss group is required). Starting at week 8 the visits are decreased to every 4 weeks. Biopsies, metabolic tests, and regional fat scans are completed at baseline, week 6, and end of study (week 22).
Treatment: Tirzepatide
- Diet-controlledNo study treatment, for comparison
The group assigned to dietary weight loss will undergo intensive dietary counseling with initial 3 day food diary evaluation followed by specific dietary recommendations that include macronutrient balanced, healthful and calorie-restricted diet, weekly dietitian visits, alternating between video and in person, use of a mobile app for food logging, weekly weights at home and biweekly weights, and review of these data by the study dietitian who will give individualized feedback at the weekly visits in order to attain targeted weight loss of 0.6 kg per week. The goal is to match weight loss in the tirzepatide and diet groups for the first six weeks. Any residual differences in weight loss at 6 weeks will be adjusted statistically. At six weeks all baseline tests (biopsy, metabolic tests, and regional fat scans) will be repeated, after which no further attempts for matching for weight loss will occur. At the end of the study (week 22), all baseline testing will occur again.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
- Plain-language title
- Tests tirzepatide for weight loss and fat tissue health in adults with obesityGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT05912621, who can take part
- Record updated
- 4 December 2024